The Influence of Concomitant Administration of Simvastatin at Different Doses with Metoprolol on Heart Rate and Blood Pressure in Normocholesterolemic

original papers Adv Clin Exp Med 2011, 20, 1, 39 45 ISSN 1230-025X Copyright by Wroclaw Medical University Jacek Owczarek, Magdalena Jasińska, Urszula Kurczewska, Daria Orszulak-Michalak The Influence of Concomitant Administration of Simvastatin at Different Doses with Metoprolol on Heart Rate and Blood Pressure in Normocholesterolemic and Hypercholesterolemic Rats* Wpływ łącznego podania simwastatyny w różnych dawkach z metoprololem na częstość rytmu serca oraz ciśnienie tętnicze u szczurów z zaburzeniami i bez zaburzeń lipidowych Department of Biopharmacy, Medical University of Lodz, Poland Abstract Background. β 1 -adrenergic blocking drugs and inhibitors of HMGCo-A reductase (statins) are widely used by a lot of patients in the prevention of cardiovascular events. Previous studies have shown that the administration of statins influences β adrenergic signaling. Objectives. The aim of the study was to evaluate the influence of a chronic 4-week administration of simvastatin given at different doses with concomitant metoprolol on heart rate and blood pressure. Material and Methods. The experiments were performed in normotensive Wistar rats. The animals were divided into 2 groups: normocholesterolemic and hypercholesterolemic. During the 4 weeks, hypercholesterolemic rats received a diet with 5% cholesterol and 2,5% cholic acid. Drugs: metoprolol 30 mg kg 1 b.w.; simvastatin 1 mg kg 1 b.w.; simvastatin 20 mg kg 1 b.w.; simvastatin 1 mg kg 1 b.w. + metoprolol 30 mg kg 1 b.w., or simvastatin 20 mg kg 1 b.w. + metoprolol 30 mg kg 1 b.w. were given intragastrically over the 4-week period. For the evaluation of heart rate and blood pressure, the signals were provided by an Isotec pressure transducer. Results. Concomitant administration of simvastatin at 1 and 20 mg kg 1 b.w with metoprolol in normocholesterolemic rats statistically decreased heart rate as compared to the control group and the group receiving simvastatin alone. No statistical differences between the groups receiving simvastatin at dose 1 mg/kg 1 with metoprolol and simvastatin at dose 20 mg/kg 1 with metoprolol (381.64 ± 7.90 vs. 388.21 ± 5,15 1/min p = 0.05) were observed. In the hypercholesterolemic animals, the heart rate evaluation after concomitant administration of simvastatin given at different doses with metoprolol showed comparable statistical implications as compared to normocholesterolemic rats. Concomitant administration of simvastatin in different doses on normo- and hypercholesterolemic rats did not significantly influence blood pressure. Conclusions. No significant impact of chronic administration of simvastatin given at different doses to normoand hypercholesterolemic Wistar rats receiving metoprolol on the heart rate was observed (Adv Clin Exp Med 2011, 20, 1, 39 45). Key words: rats, simvastatin, metoprolol, heart rate. Streszczenie Wprowadzenie. Leki blokujące receptory β 1 -adrenergiczne oraz inhibitory reduktazy 3-hydroksy 3-metyloglutarylo-koenzymu A (statyny) są powszechnie stosowane u pacjentów w zapobieganiu incydentom sercowo-naczyniowym. Wcześniejsze badania wykazały, że podawanie statyn wpływa na sygnalizację β-adrenergiczną. Cel pracy. Ocena wpływu podawania simwastatyny w różnych dawkach na wartości rytmu serca i ciśnienia tętniczego po łącznym 4-tygodniowym podawaniu z metoprololem. Materiał i metody. Badanie zostało przeprowadzone na szczurach Wistar o prawidłowym ciśnieniu krwi. Zwierzęta *The study was supported by Medical University of Lodz; grant 502-13-617; 502-13-489; 502-30-11-2.

40 J. Owczarek et al. scheduled prior to the beginning of the experiment. After the adaptation period, the animals were divided into 2 groups: normocholesterolemic and hypercholesterolemic. Normocholesterolemic rats received a normal diet during the 4 weeks. Hypercholesterolemic rats received a normal diet with 5% cholesterol and 2,5% cholic acid during the 4 weeks. After this period, each group was divided into 6 subgroups, rats receiving, respectively: group I: placebo (0.2% methylcellulose), group II: metoprolol 30 mg kg 1 b.w.; group III: simvastatin 1 mg kg 1 b.w.; group IV: simvastatin 20 mg kg 1 b.w.; group V: simvastatin 1 mg kg 1 b.w. + metoprolol 30 mg kg 1 b.w.; group VI: simvastatin 20 mg kg 1 b.w. + metoprolol 30 mg kg 1 b.w. The drugs were given intragastrically (i.g.) over the four-week period. Animals had free access to diet (normal or hypercholesterolemic) and water. After the drug administration period, heart rate and hemodynamic parameters were measured. Surgery was performed 24 hours after administration of the last drug dose and 10 hours after the last food supply. For the subsequent surgical procedures, anesthesia was initiated by an intraperitoneal (i.p.) dose of pentobarbital sodium at 60 mg kg 1 b.w. The anesthesia was maintained by intraperitoneal bolus injections of pentobarbital sodium at 10 mg kg 1 b.w. as needed. For the measurement of the heart rate (HR) and arterial blood pressure (mean (MAP), systolic (SAP) and diastolic (DAP)), a catheter was implanted into the right carotid artery. The signals were provided by an Isotec pressure transducer connected to a direct current bridge amplifier (Hugo Sachs Elektronik). Analog signals were amplified and recorded on a computer via an A/D converter (HSE Haemodyn software for Microsoft Windows 95/98/NT) and were evaluated according to the algorithms. The values of MAP, SAP and DAP were calculated automatically by the software during the measurebyły podzielone na 2 grupy: z prawidłowym stężeniem cholesterolu i podwyższonym stężeniem cholesterolu. Szczury z grupy z podwyższonym stężeniem cholesterolu otrzymywały dietę wzbogaconą 5% zawartością cholesterolu i 2,5% zawartością kwasu cholowego. Leki: metoprolol 30 mg kg 1 m.c.; simwastatyna 1 mg kg 1 m.c.; simwastatyna 20 mg kg 1 m.c.; simwastatyna 1 mg kg 1 m.c. + metoprolol 30 mg kg 1 m.c., simwastatyna 20 mg kg 1 m.c. + metoprolol 30 mg kg 1 m.c. były podawane dożołądkowo przez okres 4 tygodni. Wyniki. Łączne podanie simwastatyny w dawkach: 1 i 20 mg kg 1 m.c. z metoprololem szczurom z grupy z prawidłowym stężeniem cholesterolu znacząco statystycznie zwalniało rytm serca w porównaniu z grupą kontrolną oraz grupy otrzymującej samą simwastatynę. Nie odnotowano istotnej statystycznie różnicy w zakresie rytmu serca między osobnikami z grup z prawidłowym stężeniem cholesterolu otrzymującymi różne dawki simwastatyny (1 i 20 mg kg 1 m.c.) łącznie z metoprololem (381,64 ± 7.90 vs 388,21 ± 5,15 1/min p = 0,05). W grupie zwierząt z hipercholesterolemią ocena wartości rytmu serca po łącznym podaniu różnych dawek simwastatyny (1 i 20 mg kg 1 m.c.) łącznie z metoprololem wykazywała podobną zależność statystyczną. Łączne podanie różnych dawek simwastatyny łącznie z metoprololem nie wpłynęło istotnie statystycznie na wartości ciśnienia tętniczego. Wnioski. Nie zaobserwowano wpływu przewlekłego podawania simwastatyny w różnych dawkach na zwolnienie rytmu serca u szczurów z prawidłowym i podwyższonym stężeniem cholesterolu otrzymujących metoprolol (Adv Clin Exp Med 2011, 20, 1, 39 45). Słowa kluczowe: szczury, simwastatyna, metoprolol, rytm serca. Cholesterol-lowering drugs such as inhibitors of 3-hydroxy 3-methylglutaryl-coenzyme A reductase (HMG-CoA, statins), are widely used by a lot of patients in the prevention of cardiovascular events [1, 2]. It is connected with the LDL-cholesterol lowering activities as well as the pleiotropic effects of statins [3, 4]. Lowering criteria including both LDL-cholesterol and total cholesterol blood level in patients with cardiovascular disease requires higher doses of statins for optimization of hypolipemic therapy. β 1 -adrenergic blocking drugs are recommended for reduction of myocardial ischemia and prevention of angina pectoris. They have been shown to decrease mortality and sudden death particularly by reduction resting heart rate and in this case by reduction of myocardial oxygen consumption in patients with ischemic heart disease and heart failure [5 8]. Previous studies have shown that statins might influence β-adrenergic signaling [9] although in our studies, two-week administration of simvastatin in different doses to normocholesterolemic rats did not modify metoprolol injection-induced depressed heart rate and does not modify metoprolol s impact on blood pressure [10, 11]. The aim of the study was to evaluate the influence of simvastatin given at different doses on heart rate and blood pressure with concomitant chronic 4-week administration of metoprolol. Material and Methods Animals The study was approved by the Ethics Committee of the Medical University of Lodz (Poland) 43/ŁB405/2008. The experiments were performed on 101, anesthetized Wistar rats, outbred males. A several-day adaptation period was

Dose-dependent Interaction of Simvastatin and Metoprolol in Rats 41 ment procedure. For further statistical analysis, the output values of the parameters were calculated as the mean from 3-min periods. After heart rate and blood pressure assessment, 0.25 ml of blood samples were taken for a further lipid profile examination. Surgical procedures and recording of heart rate and blood pressure were provided as described previously [10, 11]. Statistics All data were presented as means ± SD (standard deviation). Statistical comparisons between baseline conditions and metoprolol injection were done by paired Student s t-test. Comparisons between the groups were performed using ANOVA. Post-hoc comparisons were performed using an LSD test. Normal distribution of parameters was checked by means of a Shapiro-Wilks test. If data were not normally distributed or the values of variance were different, ANOVA with Kruscal-Wallis and Mann-Whitney s U tests were used. All parameters were considered statistically significantly different if p < 0.05. The statistical analysis of the heart rate and hemodynamic parameters was performed using Statgraphics 5.0 plus software. Results Four-week administration of simvastatin alone or concomitant administration with metoprolol to normocholesterolemic rats significantly decreased LDL cholesterol and increased HDL cholesterol level as compared to the control group. A decrease of LDL cholesterol level after administration of simvastatin alone or concomitant administration with metoprolol was observed in hypercholesterolemic rats. The changes in animal lipid profiles are shown in Table 1. Table 1. Total cholesterol (TCH), HDL cholesterol, LDL cholesterol(ldl), triglycerides (TG) (mean ± SD) in rats fed normo- and hypercholesterolemic diet [mmol/l] Tabela 1. Cholesterol całkowity (TCH), HDL cholesterol, LDL cholesterol (LDL), triglicerydy (TG) (średnie ± SD) u szczurów na diecie normalnej i hipercholesterolowej [mmol/l] TCH HDL LDL TG K_N (N = 10) 1.48 ± 0.12 0.38 ± 0.09 0.95 +/-0.29 0.32 ± 0.13 M_N (N = 9) 1.14 ± 0.08 0.36 ± 0.08 0.89 +/ - 0.17 0.28 ± 0.08 S1_N (N = 10) 1.34 ± 0.21 0.57 ± 0.05* 0.56 ± 0.14* 0.46 ± 0.14 S20_N (N = 7) 1.39 ± 0.14 0.69 ± 0.14* 0.44 ± 0.09* 0.56 ± 0.18 S1_M_N (N = 6) 1.51 ± 0.14 0.60 ± 0.13* 0.62 ± 0.09* 0.58 ± 0.26 S20_M_N (N = 8) 1.32 ± 0.12 0.54 ± 0.18* 0.56 ± 0.10* 0.43 ± 0.15 K_H (N = 10) 8.09 ± 1.53 0.36 ± 0.09 6.25 ± 0.65 3.24 ± 0.62 M_H (N = 9) 7.65 ± 1.15 0.39 ± 0.13 5.38 ± 0.82 3.57 ± 0.15 S1_H (N = 8) 6.35 ± 1.81 0.61 ± 0.12* 4.45 ± 0.21* 2.82 ± 0.57 S20_H (N = 9) 2.01 ± 0.16* 0.42 ± 0.14 1.29 ± 0.92* 0.65 ± 0.64* S1_M_H (N = 8) 7.23 ± 0.66 0.41 ± 0.05 5.08 ± 0.33* 3.47 ± 0.79 S20_M_H (N = 7) 1.32 ± 0.18* 0.33 ± 0.04 0.54 ± 0.03* 0.89 ± 0.23* K_N normocholesterolemic control group, K_H hypercholesterolemic control group, M_H hypercholesterolemic group receiving metoprolol, M_N normocholesterolemic group receiving metoprolol, S1_N normocholesterolemic group receiving simvastatin at dose 1 mg/kg b.w., S1_H hypercholesterolemic group receiving simvastatin at dose 1 mg/ kg b.w., S20_N normocholesterolemic group receiving simvastatin at dose 20 mg/kg b.w., S20_H hypercholesterolemic group receiving simvastatin at dose 20 mg/kg b.w., S1_M_N normocholesterolemic group receiving metoprolol and simvastatin at dose 1 mg/kg b.w., S20_M_N normocholesterolemic group receiving metoprolol and simvastatin at dose 20 mg/kg b.w., S1_M_H hypercholesterolemic group receiving metoprolol and simvastatin at dose 1 mg/kg b.w., S20_M_H hypercholesterolemic group receiving metoprolol and simvastatin at dose 20 mg/kg b.w. (*) P < 0.05 as compared to the control group. K_N grupa kontrolna normocholesterolowa, K_H grupa kontrolna hipercholesterolowa, M_H grupa hipercholesterolowa otrzymująca metoprolol, M_N grupa normocholesterolowa otrzymująca metoprolol, S1_N grupa normocholesterolowa otrzymująca simwastatynę w dawce 1 mg/kg m.c., S1_H grupa hipercholesterolowa otrzymująca simwastatynę w dawce 1 mg/kg m.c., S20_N grupa normocholesterolowa otrzymująca simwastatynę w dawce 20 mg/kg m.c., S20_H grupa hipercholesterolowa otrzymująca simwastatynę w dawce 20 mg/kg m.c., S1_M_N grupa normocholesterolowa otrzymująca metoprolol i simwastatynę w dawce 1 mg/kg m.c., S20_M_N grupa normocholesterolowa otrzymująca metoprolol i simwastatynę w dawce 20 mg/kg m.c., S1_M_H grupa hiperchlesterolowa otrzymująca metoprolol i simwastatynę w dawce 1 mg/kg m.c., S20_M_H grupa hipercholesterolowa otrzymująca metoprolol i simwastatynę w dawce 20 mg/kg m.c. (*) P < 0.05 w porównaniu z grupą kontrolną.

42 J. Owczarek et al. Fig. 1. Mean heart rate [beats/min] in Wistar rats fed normo- and hypercholesterolemic diet K_N normocholesterolemic control group, K_H hypercholesterolemic control group, M_H hypercholesterolemic group receiving metoprolol, M_N normocholesterolemic group receiving metoprolol, S1_N normocholesterolemic group receiving simvastatin at dose 1 mg/kg b.w., S1_H hypercholesterolemic group receiving simvastatin at dose 1 mg/kg b.w., S20_N normocholesterolemic group receiving simvastatin at dose 20 mg/kg b.w., S20_H hypercholesterolemic group receiving simvastatin at dose 20 mg/ kg b.w., S1_M_N normocholesterolemic group receiving metoprolol and simvastatin at dose 1 mg/kg b.w., S20_M_N - normocholesterolemic group receiving metoprolol and simvastatin at dose 20 mg/kg b.w., S1_M_H hypercholesterolemic group receiving metoprolol and simvastatin at dose 1 mg/kg b.w., S20_M_H hypercholesterolemic group receiving metoprolol and simvastatin at dose 20 mg/kg b.w. (*) P < 0.05 as compared to the control group. (a) p < 0.05 as compared to the group receiving simvastatin alone Ryc. 1. Średnie wartości rytmu serca [liczba uderzeń/min] u szczurów Wistar na diecie normo- i hipercholesterolowych K_N grupa kontrolna normocholesterolowa, K_H grupa kontrolna hipercholesterolowa, M_H grupa hipercholesterolowa otrzymująca metoprolol, M_N grupa normocholesterolowa otrzymująca metoprolol, S1_N grupa normocholesterolowa otrzymująca simwastatynę w dawce 1 mg/ kg m.c., S1_H grupa hipercholesterolowa otrzymująca simwastatynę w dawce 1 mg/kg m.c., S20_N grupa normocholesterolowa otrzymująca simwastatynę w dawce 20 mg/kg m.c., S20_H grupa hipercholesterolowa otrzymująca simwastatynę w dawce 20 mg/kg m.c., S1_M_N grupa normocholesterolowa otrzymująca metoprolol i simwastatynę w dawce 1 mg/kg m.c., S20_M_N grupa normocholesterolowa otrzymująca metoprolol i simwastatynę w dawce 20 mg/kg m.c., S1_M_H grupa hiperchlesterolowa otrzymująca metoprolol i simwastatynę w dawce 1 mg/kg m.c., S20_M_H - grupa hipercholesterolowa otrzymująca metoprolol i simwastatynę w dawce 20 mg/kg m.c. (*) P < 0.05 w porównaniu z grupą kontrolną. (a) p < 0,05 w porównaniu z grupą otrzymującą simwastatynę The heart rate (HR) in the control groups receiving a normo- and hypercholesterolemic diet was 433.82 ± 22.6 and 418.03 ± 29.05 beats/min (p = 0.05) respectively. The four-week administration of metoprolol to normo and hypercholesterolemic rats significantly decreased HR as compared to the control groups (390.76 ± 20.5 and 384.28 ± 21,8 1/min). In groups receiving simvastatin at 1 and 20 mg kg 1 b.w. during the 4 weeks, the HR was comparable to the control rats. No differences between groups receiving simvastatin at 1 and 20 mg/kg 1 were observed, as well. After concomitant administration of simvastatin at 1 and 20 mg kg 1 b.w. with metoprolol to normocholesterolemic rats, the HR statistically decreased as compared to the control rats and the group receiving simvastatin alone. No statistical differences between groups receiving simvastatin at 1 mg/kg 1 with metoprolol and simvastatin at 20 mg/kg 1 with metoprolol (381.64 ± 7.90 vs. 388.21 ± ± 5.15 beats/min; p = 0.05) were denoted. The HR after concomitant administration of simvastatin at 1 and 20 mg kg 1 b.w. with metoprolol to hypercholesterolemic rats showed the same statistical implications as compared to normocholesterolemic rats. No statistical differences between hypercholesterolemic groups receiving simvastatin at dose 1 mg/kg 1 with metoprolol and simvastatin at dose 20 mg/kg 1 with metoprolol were shown, as well (380.76 ± 21.64 vs 382.20 ± ± 15.98 beats/min) (Fig. 1). Concomitant administration of simvastatin at 1 and 20 mg kg 1 b.w. with metoprolol in normoand hypercholesterolemic rats did not significantly influence arterial blood pressure. The results of MAP, SAP and DAP are presented in Tab. 2. Discussion In our study, concomitant administration of simvastatin given at different doses with metoprolol did not influence the heart rate as compared to rats receiving metoprolol alone. Similar effects were observed in our previous studies [10, 11]. Conversely, some reports on the influence of

Dose-dependent Interaction of Simvastatin and Metoprolol in Rats 43 Table 2. Summary statistics (mean ± SD) for arterial blood pressure [mm Hg] in normo- and hypercholesterolemic rats Tabela 2. Statystyka opisowa (średnia ± SD) dla wartości ciśnienia tętniczego [mm Hg] u szczurów normo- i hipercholesterolowych N Systolic arterial pressure (SAP) [mm Hg] Mean arterial pressure (MAP) [mm Hg] Diastolic arterial pressure (DAP) [mm Hg] K_H 10 106.75 ± 2.39 95.28 ± 3.33 86.32 ± 3.85 K_N 10 106.17 ± 3.19 95.93 ± 3.69 83.65 ± 6.18 M_H 9 107.46 ± 3.53 95.82 ± 4.57 86.86 ± 5.80 M_N 9 106.84 ± 1.30 92.68 ± 5.70 83.89 ± 4.22 S1_H 8 104.39 ± 2.45 94.37 ± 4.85 85.97 ± 5.87 S1_M_H 8 106.81 ± 2.52 93.63 ± 6.38 85.66 ± 4.98 S1_M_N 6 105.23 ± 1.26 91.52 ± 4.10 84.05 ± 4.19 S1_N 10 106.71 ± 3.29 96.18 ± 6.29 86.33 ± 4.18 S20_H 9 105.04 +- 3.05 95.35 ± 8.56 85.46 ± 3.62 S20_M_H 7 105.42 ± 2.89 94.61 ± 6.70 85.69 ± 4.36 S20_M_N 8 104.60 ± 3.93 95.87 ± 4.57 86.67 ± 5.79 S20_N 7 107.26 ± 3.65 95.01 ± 6.80 88.29 ± 6.64 K_N normocholesterolemic control group, K_H hypercholesterolemic control group, M_H hypercholesterolemic group receiving metoprolol, M_N normocholesterolemic group receiving metoprolol, S1_N normocholesterolemic group receiving simvastatin at dose 1 mg/kg b.w., S1_H hypercholesterolemic group receiving simvastatin at dose 1 mg/ /kg b.w., S20_N normocholesterolemic group receiving simvastatin at dose 20 mg/kg b.w., S20_H hypercholesterolemic group receiving simvastatin at dose 20 mg/kg b.w., S1_M_N normocholesterolemic group receiving metoprolol and simvastatin at dose 1 mg/kg b.w., S20_M_N normocholesterolemic group receiving metoprolol and simvastatin at dose 20 /mg/kg b.w., S1_M_H hypercholesterolemic group receiving metoprolol and simvastatin at dose 1 mg/kg b.w., S20_M_H hypercholesterolemic group receiving metoprolol and simvastatin at dose 20 mg/kg b.w. K_N grupa kontrolna normocholesterolowa, K_H grupa kontrolna hipercholesterolowa, M_H grupa hipercholesterolowa otrzymująca metoprolol, M_N grupa normocholesterolowa otrzymująca metoprolol, S1_N grupa normocholesterolowa otrzymująca simwastatynę w dawce 1 mg/kg m.c., S1_H grupa hipercholesterolowa otrzymująca simwastatynę w dawce 1 mg/ /kg m.c., S20_N grupa normocholesterolowa otrzymująca simwastatynę w dawce 20 mg/kg m.c., S20_H grupa hipercholesterolowa otrzymująca simwastatynę w dawce 20 mg/kg m.c., S1_M_N grupa normocholesterolowa otrzymująca metoprolol i simwastatynę w dawce 1 mg/kg m.c., S20_M_N grupa normocholesterolowa otrzymująca metoprolol i simwastatynę w dawce 20 mg/kg m.c., S1_M_H grupa hiperchlesterolowa otrzymująca metoprolol i simwastatynę w dawce 1 mg/kg m.c., S20_M_H grupa hipercholesterolowa otrzymująca metoprolol i simwastatynę w dawce 20 mg/kg m.c. HMG-CoA reductase inhibitors on β-adrenergic receptor activity have been described. It has been shown that statins, by reducing the production of important isoprenoids like farnesyl pyrophosphate (FPP) and geranylgeranyl pyrophosphate (GGPP), could increase β-adrenergic receptor density [9]. The isoprenylation process could influence the membrane association and function of heterotrimeric G-proteins by interfering with γ- subunit (Gγ) isoprenylation [12, 13], especially the isoprenylation of signaling molecules, including the monomeric GTPases of the Rho and Ras families. Moreover, the isoprenylation of Gγ has been found to be essential for membrane attachment of Gγ as well as Gβ [14]. Previous studies demonstrated that treatment of cardiac myocytes with a statin reduced camp and induced a significant increase in β-adrenergic receptor density and, in this way, statins might have an impact on heart rate. The dose dependent influence of statins on beta1- adrenergic signaling was studied as well [9]. The clinical manifestations of the interaction of statins with β 1 -adrenergic blockers on heart rate have not been elucidated yet. Their concomitant usage does not seem to impact heart rate negatively, nor blood pressure. Concomitant administration of simvastatin at 1 and 20 mg kg 1 b.w. with metoprolol in normo- and hypercholesterolemic rats did not significantly influence blood pressure. Even so, clinical observations in the UCSD Statin Study and the Anglo-Scandinavian Cardiac Outcomes Trial- Lipid Lowering Arm (ASCOT-LLA) suggest that HMG-CoA reductase inhibitors might have some blood-pressure-lowering properties in addition to their effect on lipids [15, 16]. On the other hand, the CARE study showed no significant reduction of BP with statin therapy [2]. Different results between the CARE and ASCOT studies may result from the degree of LDL-C reduction achieved in the above trials. The laboratory studies showed the

44 J. Owczarek et al. link between statins therapy and vascular function and this could explain the beneficial pharmacological effect of statins in patients with hypertension. Statins improve endothelial function and decrease oxidative stress and inflammation [17 19]. They were shown to reduce the production of reactive oxygen species, such as superoxide anion, and hydroxyl radicals, as shown in experimental studies. This action may also contribute to the vasodilatory effects of statins. It has already been established that statins increase the endothelial production of NO and this effect is correlated with the upregulation of endothelial NO synthase expression [20]. It has suggested that the effect described above might be intensified by the simultaneous inhibition of G proteins with reduced endothelial NO synthase mrna degradation and, thus, increased NO bioavailability [21, 22]. Vascular statin activity may result from drug impact on the decrease of vasoconstrictor endothelin-1 level [21]. Another possible mechanism of statin s BP-lowering effect involves the downregulation of the angiotensin IItype 1 receptor. The angiotensin II type 1 receptor is overexpressed in hypercholesterolemic patients and it may be improved by the administration of statins, which were also shown to markedly reduce the vasoconstrictor response to angiotensin II infusion [24]. Reduction of large artery stiffness and blood pressure in normolipidemic patients with isolated systolic hypertension statins could improve systemic arterial compliance [25]. The authors concluded that administration of simvastatin in different doses not decrease slowing heart rate after chronic concomitant administration of metoprolol in normo- and hypercholesterolemic rats. References [1] Tanaka N, Katayama Y, Katsumata T, Otori T, Nishiyama Y: Effects of long-term administration of HMG-CoA reductase inhibitor, atorvastatin, on stroke events and local cerebral blood flow in stroke-prone spontaneously hypertensive rats. Brain Res 2007, 1169, 125 132. [2] Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JMO, Wun CC, Davis BR, Braunwald E: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996, 335, 1001 1009. [3] Jasińska M, Owczarek J, Orszulak-Michalak D: Statins: a new insight into their mechanisms of action and consequent pleiotropic effects. Pharmacol Rep 2007, 59, 483 499. [4] Wierzbicki AS, Chowienczyk PJ, Cockcroft JR, Brett SE, Watts GF, Jenkins BS et al.: Endothelial dysfunction is strictly connected with hypertension development and LDL-C levels. Cardiovascular risk factors and endothelial dysfunction. Clin Sci 2004, 107, 609 615. [5] Fox K, Borer JS, Camm AJ, Danhin N, Ferrari R, Lopez Sendon JL, Steg PG, Tardif J-C, Tavazzi L, Tendera M: Resting heart rate in cardiovascular disease. J Am Coll Cardiol 2007, 50, 823 830. [6] Tverdal A, Hjellvik V, Selmer R: Heart rate and mortality from cardiovascular causes: a 12 year follow-up study of 379 843 men and women aged 40 45 years. Eur Heart J 2008, 29, 2772 2781. [7] Chen ZM, Pan HC, Chen YP, Peto R, Collins R, Jiang LX, Xie JX, Liu LS: COMMIT Collaborative group. Early intravenous then oral metoprolol in 45,852 patients with acute myocardial infarction: randomized placebocontrolled trial. Lancet 2005, 366, 1622 1632. [8] Freemantle N, Cleland J, Young P, Mason J, Harrison J: Beta blockade after myocardial infarction: systematic review and meta regression analysis. BMJ 1999, 318, 1730 1737. [9] Mühlhäuser U, Zolk O, Rau T, Münzel F, Wieland T, Eschenhagen T: Atorvastatin desensitizes β-adrenergic signaling in cardiac myocytes via reduced isoprenylation of G-protein γ-subunits. The FASEB Journal Express Article 2006, doi:10.1096/fj.05-5067fje. [10] Owczarek J, Jasińska M, Orszulak-Michalak D: Dose-dependent influence of two-week administration of simvastatin and metoprolol injection on blood pressure in normocholesterolemic rats. Acta Pol Pharm Drug Res 2008, 65, 147 151. [11] Owczarek J, Jasińska M, Orszulak-Michalak D: Interaction between different doses of simvastatin after two-week administration and metoprolol injection on the heart rate in normocholesterolemic rats. Acta Pol Pharm Drug Res 2008, 65, 141 145. [12] Muntz K, Sternweis PC, Gilman AG, Mumby SM: Influence of gamma subunit prenylation and association of guanine nucleotide-binding regulatory proteins with membranes. Mol Biol Cell 1992, 3, 49 61. [13] Myung CS, Yasuda H, Liu WW, Harden TK, Garrison JC: Role of isoprenoid lipids on the heterotrimeric G protein gamma subunit in determining effector activation. J Biol Chem 1999, 274, 16595 16603. [14] Takida S, Wedegaertner PB: Heterotrimer Formation, Together with Isoprenylation, Is Required for Plasma Membrane Targeting of Gβγ. J Biol Chem 2003, 278, 17284 17290. [15] Golomb BA, Ritchie JB, Criqui MH, Dimsdale JE: Statins lower blood pressure: results from the UCSD Statin Study. Circulation 2004, 110, III 402. [16] Poulter N, Sever PS: Do statins lower blood pressure? Evidence from the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA). Circulation 2004, 110, III 402. [17] Morikawa S, Takabe W, Mataki C, Kanke T, Itoh T, Wada Y, Izumi A, Saito Y, Hamakubo T, Kodama T: The effect of statins on mrna levels of genes related to inflammation, coagulation and vascular constriction in HUVEC. Human umbilical vein endothelial cells. J Atheroscler Thromb 2002, 9, 177 183.

Dose-dependent Interaction of Simvastatin and Metoprolol in Rats 45 [18] De Jongh S, Lilien MR, op t Roodt J, Stroes ES, Bakker HD, Kastelein JJ: Early statin therapy restores endothelial function in children with familial hypercholesterolemia. J Am Coll Cardiol 2002, 40, 2117 2121. [19] Omori H, Nagashima H, Tsurumi Y, Takagi A, Ishizuka N, Hagiwara N, Kawana M, Kasanuki H: Direct in vivo evidence of a vascular statin: a single dose cerivastatin increases vascular endothelial responsiveness in healthy normocholesterolemic patients. Br J Pharmacol 2002, 54, 395 399. [20] Kalinowski L, Dobrucki LW, Brovkovych V, Malinski T: Increased nitric oxide bioavailability in endothelial cells contributes to the pleiotropic effect of cerivastatin. Circulation 2002, 105, 933 938. [21] Laufs U, Gertz K, Dirnagl U, Bohm M, Nickenig G, Endres M: Rosuvastatin a new-coa reductase inhibitor, upregulates endothelial nitric oxide synthase and protects from ischaemic stroke in mice. Brain Res 2002, 942, 23 30. [22] Strazzullo P, D Elia L, Versiero M: Response to Upregulation of Nitric Oxide, Inhibition of Oxidative Stress, and Antihypertensive Effects of Statins. Hypertension 2007, 49, 792 798. [23] Hernandez-Perera O, Perez-Sala D, Navarro-Antolin J, Sanchez-Pascuala R, Hernandez G, Diaz C, Lamas S: Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells. J Clin Invest 1998, 101, 2711 2719. [24] Nickenig G, Baumer AT, Temur Y, Kebben D, Jockenhovel F, Bohm M: Statin-sensitive dysregulated AT1 receptor function and density in hypercholesterolemic men. Circulation 1999, 100, 2131 2134. [25] Ferrier KE, Muhlmann MH, Baguet JP, Cameron JD, Jennings GL, Dart AM, Kingwell BA: Intensive cholesterol reduction lowers blood pressure and large artery stiffness in isolated systolic hypertension. J Am Coll Cardiol 2002, 39, 1020 1025. Address for correspondence: Jacek Owczarek Department of Biopharmacy Medical University of Lodz Muszyńskiego 1 90-153 Łódź Poland E-mail: jacek.owczarek@umed.lodz.pl Conflict of interest: None declared Received: 24.06.2010 Revised: 1.02.2011 Accepted: 1.02.2011